Early detection and interception of pancreatic ductal adenocarcinoma (PDAC) remain the only realistic strategies to reduce ...

Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly affects middle-aged women, ...

In chronic hepatitis B virus (HBV) infection, the central debate remains whom and when to treat. The 2025 European Association for the Study of the Liver (EASL) Clinical Practice Guidelines (CPGs)1 ...

Background Post-infection disorders of gut-brain interaction (PI-DGBI) are a subset of chronic gastrointestinal disorders triggered by acute infectious gastroenteritis. These conditions impose a ...

Correspondence to Dr Michael J Bourke, Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead 2145, New South Wales, Australia; michael{at}citywestgastro.com.au Background and aims ...

Correspondence to Hong-Yang Wang and Jin Ding, The International Cooperation Laboratory on Signal Transduction, Shanghai Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 ...

Objective Faecal microbiota transplantation (FMT) has variable efficacy in treating UC. Recently, oral lyophilised FMT was found to induce remission in patients with UC, with one donor having 100% ...

Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated interferon alpha (PegIFN-α) has ...

Objective Resection can potentially cure resectable pancreatic cancer (PaC) and significantly prolong survival in some patients. This large-scale international study aimed to investigate variations in ...

Objective Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and ...

Objective Intestinal barrier loss is a Crohn’s disease (CD) risk factor. This may be related to increased expression and enzymatic activation of myosin light chain kinase 1 (MLCK1), which increases ...

Background Non-invasive biomarkers with biological rationale are needed for identifying patients with progressive metabolic dysfunction-associated steatohepatitis (MASH). Objective To test the ...